JMP Securities maintains Cytokinetics stock with $78 target
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
JMP maintains Apollo stock Market Perform rating
JMP Securities maintained its Market Perform rating on Apollo Global Management (NYSE:APO) shares without setting a new price ...
Covers3d
Super Bowl Betting May Near $2B After ‘Customer Friendly’ NFL Season: Covers
The killing U.S. bettors made this NFL season could nudge legal sports betting on this year’s Super Bowl toward $2 billion in regulated action.
Uber Technologies Inc. (UBER): This AI Stock Is On Analysts’ Radars Right Now
Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from leading US tech firms like International Business Machines Corp. (NYSE:IBM).